- Home
- EDIT vs UHG Comparison
EDIT vs UHG Comparison
Compare EDIT & UHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- UHG
- Stock Information
- Founded
- EDIT 2013
- UHG 2004
- Country
- EDIT United States
- UHG United States
- Employees
- EDIT N/A
- UHG N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- UHG Homebuilding
- Sector
- EDIT Health Care
- UHG Consumer Discretionary
- Exchange
- EDIT Nasdaq
- UHG Nasdaq
- Market Cap
- EDIT 263.7M
- UHG 242.0M
- IPO Year
- EDIT 2016
- UHG N/A
- Fundamental
- Price
- EDIT $2.28
- UHG $4.06
- Analyst Decision
- EDIT Buy
- UHG
- Analyst Count
- EDIT 12
- UHG 0
- Target Price
- EDIT $6.20
- UHG N/A
- AVG Volume (30 Days)
- EDIT 2.2M
- UHG 225.8K
- Earning Date
- EDIT 08-19-2025
- UHG 08-07-2025
- Dividend Yield
- EDIT N/A
- UHG N/A
- EPS Growth
- EDIT N/A
- UHG N/A
- EPS
- EDIT N/A
- UHG 0.10
- Revenue
- EDIT $35,837,000.00
- UHG $445,963,017.00
- Revenue This Year
- EDIT N/A
- UHG N/A
- Revenue Next Year
- EDIT N/A
- UHG N/A
- P/E Ratio
- EDIT N/A
- UHG $5.32
- Revenue Growth
- EDIT N/A
- UHG 7.51
- 52 Week Low
- EDIT $0.91
- UHG $1.60
- 52 Week High
- EDIT $4.90
- UHG $6.93
- Technical
- Relative Strength Index (RSI)
- EDIT 43.28
- UHG 58.87
- Support Level
- EDIT $2.37
- UHG $3.60
- Resistance Level
- EDIT $2.67
- UHG $4.49
- Average True Range (ATR)
- EDIT 0.23
- UHG 0.34
- MACD
- EDIT -0.08
- UHG -0.00
- Stochastic Oscillator
- EDIT 5.37
- UHG 74.72
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.